ION-859 is under clinical development by Ionis Pharmaceuticals and currently in Phase II for Parkinson's Disease.

INR:7277. rummy arrs Priced at RMB 2.37 million per year, SMA treatment drug Spinraza faces new competitor amid controversy Allergan successfully joins the "rich famil ...

MOR-210 is under development for the treatment of autoimmune disorders, cancer including relapsed or refractory advanced solid tumors. It is administered parenterally through intravenous route. The ...

INR:7627. odds on that betfair A shot of Biogen's SMA drug costs 700,000 yuan in China and 200 yuan abroad. Why is it so expensive? 9 drug marketing applicat ...

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

Swiss drugmaker Novartis said on Monday its gene therapy helped improve motor function in children with a rare muscle ...

Born with spinal muscular atrophy (SMA), a rare disease that causes progressive muscle degeneration and weakness, I have ...

Learn about Ionis Pharmaceuticals' innovative RNA-targeted therapy and their potential for significant revenue growth. Read ...

1 number Not willing to lag behind SMA gene therapy Zolgensma, Biogen launches high-dose trial of Spinraza BMS's second three-drug regimen, Empliciti, is approved by the European Union to treat ...